F543-0589 Screening compound: N-{[3-(1-cyclopentyl-2-oxo-2,3-dihydro-1H-1,3-benzodiazol-5-yl)-1,2,4-oxadiazol-5-yl]methyl}benzamide

F543-0589 Screening compound: N-{[3-(1-cyclopentyl-2-oxo-2,3-dihydro-1H-1,3-benzodiazol-5-yl)-1,2,4-oxadiazol-5-yl]methyl}benzamide
F543-0589 Screening compound: N-{[3-(1-cyclopentyl-2-oxo-2,3-dihydro-1H-1,3-benzodiazol-5-yl)-1,2,4-oxadiazol-5-yl]methyl}benzamide alternative view

Chemical Structure Depiction of ChemDiv screening compound F543-0589
N-{[3-(1-cyclopentyl-2-oxo-2,3-dihydro-1H-1,3-benzodiazol-5-yl)-1,2,4-oxadiazol-5-yl]methyl}benzamide

Available from 1 mg

Formats:

  • Glass Vials (4ml Glass Vials VWR #97047-678)
  • 96-tube racks (Matrix #4247 96-well 1.4ml sealed with capmats, empty cols 1 & 12, 100uL of 10mM)

Shiptime: 1 week worldwide delivery in most cases

Compound Identifiers

ChemDiv Compound ID

F543-0589

Molecular Formula

C22H21N5O3 (C22 H21 N5 O3)

Compound Name

N-{[3-(1-cyclopentyl-2-oxo-2,3-dihydro-1H-1,3-benzodiazol-5-yl)-1,2,4-oxadiazol-5-yl]methyl}benzamide

IUPAC name

N-{[3-(1-cyclopentyl-2-oxo-23-dihydro-1H-13-benzodiazol-5-yl)-124-oxadiazol-5-yl]methyl}benzamide

SMILES

O=C(c1ccccc1)NCc1nc(-c(cc2)cc(N3)c2N(C2CCCC2)C3=O)no1

InChI

InChI=1S/C22H21N5O3/c28-21(14-6-2-1-3-7-14)23-13-19-25-20(26-30-19)15-10-11-18-17(12-15)24-22(29)27(18)16-8-4-5-9-16/h1-3,6-7,10-12,16H,4-5,8-9,13H2,(H,23,28)(H,24,29)

InChI Key

ABQQOUHOTHWQNF-UHFFFAOYSA-N

MDL Number (MFCD)

MFCD27175280

Chemical and Physical Properties

Saltdata

n/a

Molecular Weight

403.44

Hydrogen Bond Acceptors Count

7.00

Hydrogen Bond Donors Count

2.00

Rotatable Bond Count

6.00

Number of Nitrogen and Oxygen Atoms

8

Partition Coefficient, logP

4.458

Distribution Coefficient, logD

4.458

Water Solubility, LogSw

-4.51

Polar Surface Area

82.406

Acid Dissociation Constant (pKa)

11.79

Base Dissociation Constant (pKb)

-1.22

Number of Chiral Centers

0.00

Percent sp3 carbon bonding

27.30

F543-0589 in Drug Discovery

Included in Screening Libraries

Allosteric Kinases Inhibitors Library (23117 compounds)

Antiviral Library (67538 compounds)

300k Representative Compounds Library (Bemis-Murcko Clustering Algorithm) (286253 compounds)

GPCR Targeted Library (31838 compounds)

Hsp90-Targeted Library (11355 compounds)

KRAS-Targeted Library (16000 compounds)

Lipid Metabolism Library (9174 compounds)

Included in 1.7M Stock Database

Therapeutical areas:
  • Cancer
  • Female
  • Congenital
  • Skin
  • Antiviral
  • Infections
  • Immune system
  • Musculoskeletal
  • Respiratory tract
  • Nervous system
  • Congenital
  • Skin
  • Metabolic
  • Endocrine
  • Cancer
  • Digestive system
  • Respiratory tract
  • Male
  • Female
  • Hemic and lymphatic
  • Immune system
  • Cancer
  • Digestive system
  • Respiratory tract
  • Otorhinolaryngologic
  • Cardiovascular
  • Metabolic
Targets:
  • Kinases
  • GPCR
  • Kinases
Mechanism of action:
  • Receptor's ligands

References: we are preparing a list of scientific research reports with F543-0589 chemical compound. It will be published here after verification.

Frequently Asked Questions

How to purchase chemical compound F543-0589?
Check Price and Availability of F543-0589, then you can add required amount to the Shopping Cart. In the Shopping Cart you can again refine your selection. Once you are sure that it’s exactly what you want you can move forward with the Checkout (to pay online by credit card, or via PayPal), or Request a Quote.
What is the minimum amount of F543-0589 you sell to drug discovery company or institution?
Available from 1 mg in Glass Vials or 96-tube racks.
Delivery options for F543-0589
ChemDiv sends parcels with Express services (UPS, WC).
  • 1–2 days for small orders
  • 2–4 weeks for large selections
Delivery formats for F543-0589
  • 0.5–50 mg of dry powder sample in single glass vials, custom vials
  • DMSO solutions frozen 10μl–250μl@10mM (96 and 384 format)

Custom synthesis of F543-0589 available by request